公开(公告)号：US09364469B1

公开(公告)日：2016-06-14

申请号：US14925996

申请日：2015-10-29

Applicant: Macau University of Science and Technology

Inventor： Lai-Han Leung ,  Xiao-Jun Yao ,  Kam Wai Wong ,  Liang Liu ,  Xi Chen

IPC: A61K31/4439

CPC classification number: A61K31/4439

Abstract: The present invention discloses a method of treating gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of D561-0775. A pharmaceutical composition comprising D561-0775 admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.

Abstract translation: 本发明公开了一种治疗耐吉非替尼的非小细胞肺癌的方法，包括给予有效量的D561-0775。 还公开了包含D561-0775的药物组合物，其与药物载体混合以治疗吉非替尼耐药性非小细胞肺癌。

公开(公告)号：US10369127B2

公开(公告)日：2019-08-06

申请号：US15632738

申请日：2017-06-26

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Man Chung Wong

IPC: A61K31/28 ,  A61K31/555 ,  A61K45/06

Abstract: A method for inhibiting the expression and/or functional activity of an ABC transporter protein in a subject suffering from a disorder associated with an overexpression of the ABC transporter protein includes administrating a cobalt-polypyridyl complex to the subject. A method for inhibiting the expression and/or functional activity of an ABC transporter in cells includes contacting the cells with an effective amount of the cobalt-polypyridyl complex.

公开(公告)号：US09675608B2

公开(公告)日：2017-06-13

申请号：US14925962

申请日：2015-10-28

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Liang Liu

IPC: A61K31/44 ,  A61K31/4745

CPC classification number: A61K31/4745

Abstract: The present invention discloses a method of treating cancer and/or multidrug-resistant cancer, comprising administering an effective amount of hernandezine or thalidezine. A pharmaceutical composition comprising hernandezine or thalidezine admixed with a pharmaceutical carrier for treating cancers and/or multidrug-resistant cancer is also disclosed.

公开(公告)号：US09561222B2

公开(公告)日：2017-02-07

申请号：US14985419

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Liang Liu ,  Jingrong Wang

IPC: A61K31/4725 ,  A61K31/4745 ,  A61K31/4748

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US09561219B2

公开(公告)日：2017-02-07

申请号：US14985408

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Liang Liu ,  Jingrong Wang

IPC: A61K31/4725 ,  A61K31/4745 ,  A61K31/4748

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US09119847B2

公开(公告)日：2015-09-01

申请号：US14562780

申请日：2014-12-08

Applicant: Macau University of Science and Technology

Inventor： Yuen Kwan Law ,  Kam Wai Wong ,  Liang Liu

IPC: A61K31/4725 ,  A61K36/185

CPC classification number: A61K31/4725 ,  A61K36/62

Abstract: The present invention discloses a method of treating neurodegenerative disorder comprising administering an effective amount of an alkaloid which is a bisbenzylisoquinline alkaloid isolated from the traditional Chinese medicinal herb Nelumbo nucifera. The pharmaceutical composition thereof for treating Huntington's disease is also disclosed.

Abstract translation: 本发明公开了一种治疗神经变性疾病的方法，包括给予有效量的生物碱，所述生物碱是从中草药Nelumbo Nucumera分离的双苄基异喹啉生物碱。 还公开了其用于治疗亨廷顿病的药物组合物。

公开(公告)号：US09051348B2

公开(公告)日：2015-06-09

申请号：US14040738

申请日：2013-09-30

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Liping Bai ,  Hang Dong ,  Kam Wai Wong ,  Zhihong Jiang ,  Hua Zhou

IPC: C07J17/00

CPC classification number: C07J17/005

Abstract: The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.

Abstract translation: 本发明涉及一种衍生自人参皂苷Rh2的新型化合物，其制备方法及其在治疗癌症中的应用。

公开(公告)号：US20180085413A1

公开(公告)日：2018-03-29

申请号：US15280136

申请日：2016-09-29

Applicant: Macau University of Science and Technology

Inventor： Yuen Kwan Law ,  Kam Wai Wong ,  An Gao Wu ,  Liang Liu ,  Zeng Wu

IPC: A61K36/25 ,  A61K31/704 ,  A61K31/56

CPC classification number: A61K36/25 ,  A61K31/19 ,  A61K31/56 ,  A61K31/704 ,  A61K2236/33 ,  A61K2236/35 ,  A61K2236/39 ,  A61P25/28

Abstract: A method for treating a subject suffering from a neurodegenerative disease includes administering at least one triterpenoid which can be obtained from Hedera helix. A method for treating a subject suffering from a neurodegenerative disease includes administering an effective amount of a Hedera helix extract which comprises the triterpenoid. The neurodegenerative disease is preferably but not exclusively Parkinson's disease or Huntington's disease. Methods for extracting the triterpenoid from Hedera helix and a method for inducing autophagy in cells by contacting them with the triterpenoid are also provided. The triterpenoid allows an exceptional induction of autophagy, in particular a significant reduction of the protein level of mutant huntingtin, a significant reduction of the protein level of A53T α-synuclein, a significant inhibition of the oligomerization of α-synuclein and a significant inhibition of the inclusion formation of huntingtin via the AMPK-mTOR dependent autophagy inducing pathway.

公开(公告)号：US20170151212A1

公开(公告)日：2017-06-01

申请号：US14953860

申请日：2015-11-30

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Onat Kadioglu ,  Liang Liu

IPC: A61K31/352 ,  A61K31/337 ,  A61K31/704

CPC classification number: A61K31/352 ,  A61K31/337 ,  A61K31/704 ,  A61K2300/00

Abstract: Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant.Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.

公开(公告)号：US20170128394A1

公开(公告)日：2017-05-11

申请号：US14971153

申请日：2015-12-16

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Su-Wei Xu ,  Sami Hamdoun ,  Liang Liu

IPC: A61K31/19 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/337 ,  A61K33/24

CPC classification number: A61K31/19 ,  A61K31/337 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/24 ,  A61K2300/00

Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.